A preparation process of a composition containing phenylephrine hydrochloride
By using citrate to stabilize phenylephrine hydrochloride under pH 4.5-5.0, combined with shear mixing process and auxiliary agents, the problem of low stability and dissolution of phenylephrine hydrochloride preparations was solved, and the efficacy was improved and bioavailability, suitable for the treatment of a variety of respiratory diseases, but attention should be paid to the contraindications for people under 4 years old.
Patent Information
- Application Number
- CN202010417513.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-05-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-05-15
AI Technical Summary
During the preparation process, the existing phenylephrine hydrochloride preparations cause discoloration of the medicine liquid and degradation of active ingredients, which reduce the efficacy and may cause side effects, and have low dissolution, poor bioavailability and efficacy. .
Using citric acid or other acids to stabilize phenylephrine hydrochloride under conditions of pH 4.5-5.0, especially preferably pH 4.7-5.0, use citric acid or other acids to stabilize phenylephrine hydrochloride, and prepare a stable mixing process through the combination of shear mixing process and auxiliary agents. Suspensions ensure high dissolution and bioavailability of the drug.
It realizes the stability and high dissolution of phenylephrine hydrochloride, improves the efficacy of the drug, ensures the simplicity and stability of the preparation method, and is also suitable for the treatment of symptoms such as fever, sore throat, nasal congestion, and cough, but not Suitable for people under 4 years old.
Smart Images

Figure CN111773203B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of drug research and development, and specifically relates to a preparation process of a composition containing phenylephrine hydrochloride. More specifically, the preparation process is a preparation process of a suspension. Background Art
[0002] Respiratory diseases include a variety of diseases, most of which are caused by viruses or bacteria, such as colds, flu, and allergic rhinitis. The main symptoms are fever, nasal congestion, runny nose, cough, sneezing or headache. If not treated in time, they can cause many complications and cause serious harm to people's bodies.
[0003] Phenylephrine hydrochloride is an alpha adrenergic receptor agonist and is often used in combination with antihistamines, antitussives, expectorants, antipyretics, anti-inflammatory drugs and other drugs for the treatment of respiratory diseases such as colds and flu. It mainly plays a role in mucosal contraction to increase the efficacy of expectoration and the treatment of nasal congestion, rhinitis, etc.
[0004] There are many single or compound preparations containing phenylephrine hydrochloride, such as injections, tablets, capsules, eye drops, etc. It is known to those skilled in the art that when preparing suitable products, the primary issues that must be considered are the stability of the drug and the release rate of the drug. Therefore, the selection of dosage forms and the setting of process parameters are challenging tasks. Specifically, when preparing oral liquids, if the formulation is unreasonable or the process conditions are not considered during preparation, the liquid may change color or the active ingredients may degrade, which may reduce the efficacy and produce side effects.
[0005] The invention patent with the patent number of "2007800304895" and the patent name of "pharmaceutical suspension containing phenylephrine and preparation method thereof" discloses a pharmaceutical suspension and related methods thereof, and its embodiments 1 to 4 are its preferred preparation methods, and the method is roughly as follows: (1) adding a certain amount of water to a mixer with a high shear function; (2) adding microcrystalline cellulose and carboxymethyl cellulose, and shearing at 880R / S for about 20 minutes; (3) adding glycerol and dextromethorphan hydrobromide, and shearing and mixing at 880R / S for about 20 minutes until dissolved; (4) adding xanthan gum, Shear mix at 880R / S for about 20 minutes until hydrated; (5) add sodium sorbitol and sucrose, and shear mix at 450R / S for 30 minutes; (6) add citric acid, sodium benzoate, chlorpheniramine maleate and phenylephrine hydrochloride, and shear mix at 880R / S for 30 minutes; (7) add acetaminophen (fine powder grade), dyes and flavorings, and shear mix at 880R / S for 20 minutes; (8) add purified water to the final volume, and vacuum degas at a vacuum degree of 4.0psia (pounds per square inch absolute) to obtain (all mixing steps are carried out under vacuum).
[0006] The inventors found that the suspension prepared by the method has high viscosity, and the longer the shear mixing time, the greater the viscosity. After sampling and testing the dissolution at 5 different times (using the contents of phenylephrine hydrochloride, chlorpheniramine maleate, dextromethorphan hydrobromide and acetaminophen as detection indicators), the dissolution is less than 60%, which shows that the low solubility means low bioavailability and corresponding low therapeutic effect. Summary of the invention
[0007] The invention is briefly described as follows:
[0008] The present invention comprises a preparation process of a phenylephrine hydrochloride composition, wherein the active ingredients of the composition include phenylephrine hydrochloride, chlorpheniramine maleate, acetaminophen and dextromethorphan hydrobromide, and the suspension prepared also contains certain thickeners, cosolvents, pH regulators, suspending agents, preservatives, flavoring agents, etc. In the present invention, phenylephrine hydrochloride can be degraded in the presence of oxygen, aldehydes, certain acids and metals. It is found through research that the suspension prepared by the method of the present invention is stable at a pH value of 4.5-5.0, preferably a pH value of 4.7-5.0, when containing citric acid or other acids. The specific method is roughly as follows: firstly, the suspending agent is shear-mixed, and then, when the dextromethorphan hydrobromide component is not included, the uniformly shear-mixed suspending agent is shear-mixed with chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and other dissolved / or molten liquids and their auxiliary materials, and finally, dextromethorphan hydrobromide is added for mixing, the solvent is adjusted to the prepared amount, and the pH value is adjusted by adding a pH regulator. The suspension prepared by this method has the advantages of simple preparation method, stable drug solution, high solubility and high bioavailability.
[0009] It should be noted that the composition of the present invention can be made into other forms such as suspensions, mixtures, syrups, and other oral liquid preparations, as well as liquid-filled capsules, liquid-filled sugar cubes, and the like.
[0010] The invention has a special effect on fever, sore throat, nasal congestion, cough, runny nose, etc. However, it is not suitable for people under 4 years old, and those aged 4-6 years old should follow the doctor's advice.
[0011] The invention is described in detail as follows:
[0012] Unless otherwise specified, all weights or volumes herein are based on the weighing of the active pharmaceutical ingredient in the composition and the auxiliary materials required for preparing the suspension at 18-25°C.
[0013] To realize the present invention, the technical solution of the present invention is as follows:
[0014] Prescription: 1000ml contains:
[0015] Active ingredients of the drug: 0.5g of phenylephrine hydrochloride, 0.2g of chlorpheniramine maleate, 0.032g of acetaminophen, and 1.00g of dextromethorphan hydrobromide.
[0016] Excipients: solvent 1 50-150g, solvent 2 600-800g, thickener 0.8-2.0g, suspending agent 1.00-10.00g, preservative 0.8-1.5g, flavoring agent 1.00-5.00g, pH regulator, pigment 10-40mg, flavor 1-3ml, solvent
[0017] Preparation method:
[0018] Processing of raw materials and auxiliary materials: Paracetamol: crushed, passed through 80-120 mesh sieve; pigments and flavors: first use solvents to prepare a certain concentrated solution, and set aside;
[0019] A. Take the prescribed amount of chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and preservatives and place them in a clean container, add an appropriate amount of solvent at 55-65°C, stir until molten / or dissolved, add co-solvent 2, continue stirring for 20-60 minutes, let stand, filter, and obtain material 1;
[0020] B. Take the prescribed amount of suspending agent and put it into a homogenizer, add an appropriate amount of solvent, and stir homogenously with a homogenizer (10000-20000r / s) for 20-50s to obtain material 2;
[0021] C. Transfer the above material 1 to material 2, and continue to homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 3;
[0022] D. Take the cosolvent 1 and place it in a clean container, add the thickener, stir until it is melted / or dissolved, add the prescribed amount of dextromethorphan hydrobromide, stir evenly, and stir at 55-65° C. for 30-60 minutes to obtain material 4;
[0023] E. Transfer material 3 to material 4, add the prescribed amount of flavoring agent, pigment solution, and flavor solution, add solvent to the prepared amount, stir for 100-150 minutes, adjust the pH value to 4.5-5.0 with a pH regulator, continue stirring until homogeneous, filter, and obtain the present invention.
[0024] The cosolvent 1 is glycerol, and the cosolvent 2 is sorbitol.
[0025] The thickener includes but is not limited to xanthan gum, carbomer, cross-linked sodium polyacrylate, poloxamer, polyvinyl alcohol, sodium alginate, and xanthan gum is more preferred.
[0026] The suspending agent includes but is not limited to microcrystalline cellulose, polyvinyl pyrrolidone aqueous solution or hydroxypropyl methylcellulose, one or more thereof, and microcrystalline cellulose is further preferred.
[0027] The preservatives include but are not limited to benzoic acid, sodium benzoate, sorbic acid, sodium sorbate, and sodium benzoate is more preferred.
[0028] The flavoring agent includes but is not limited to sucrose, stevioside, and sucralose, and sucralose is more preferred.
[0029] The pH regulator includes but is not limited to sodium hydrogen phosphate, anhydrous citric acid, potassium dihydrogen phosphate or sodium dihydrogen phosphate, and anhydrous citric acid is further preferred.
[0030] The pigments include but are not limited to lemon yellow, orange yellow, brilliant blue, and allura red, preferably brilliant blue and allura red.
[0031] The flavors include but are not limited to grape flavor, apple flavor, orange flavor, preferably grape flavor.
[0032] The solvent includes but is not limited to water, propylene glycol, ethanol, polyethylene glycol or a mixture thereof. The water is purified water, deionized water or distilled water. Purified water is preferred in the present invention.
[0033] The preferred prescription and preparation method of the present invention are as follows:
[0034] Prescription: 1000ml contains:
[0035] Active ingredients of the drug: 0.5g of phenylephrine hydrochloride, 0.2g of chlorpheniramine maleate, 0.032g of acetaminophen, and 1.00g of dextromethorphan hydrobromide.
[0036] Excipients: glycerol 100.00g, sorbitol 670.00g, xanthan gum 1.12g, microcrystalline cellulose 0.0075g, sodium benzoate 1.2g, sucralose 2.4g, appropriate amount of anhydrous citric acid, appropriate amount of purified water.
[0037] Preparation method:
[0038] Processing of raw materials and auxiliary materials: (1) Paracetamol, crushed, and passed through a 80-120 mesh sieve; (2) Pigments and flavors are first prepared into a certain concentrated solution with water.
[0039] A. Take the prescribed amount of chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and sodium benzoate and place them in a clean container, add an appropriate amount of purified water at 55-65°C, stir until melted / or dissolved, add sorbitol, continue stirring for 20-60 minutes, let stand, filter, and obtain material 1;
[0040] B. Take the prescribed amount of microcrystalline cellulose and place it in a homogenizer, add an appropriate amount of purified water, and homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 2;
[0041] C. Transfer the above material 1 to material 2, and continue to homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 3;
[0042] D. Place glycerol in a clean container, add xanthan gum, stir until melted / or dissolved, add the prescribed amount of dextromethorphan hydrobromide, stir evenly, and stir at 55-65° C. for 30-60 minutes to obtain material 4;
[0043] E. Transfer material 3 to material 4, add the prescribed amount of sucralose, brilliant blue, allura red, grape essence, add purified water to the preparation amount, stir for 100-150 minutes, adjust the pH value to 4.7-5.0 with anhydrous citric acid, continue stirring until homogeneous, filter, and obtain the present invention.
[0044] Beneficial Effects
[0045] The present invention comprises a preparation process of a phenylephrine hydrochloride composition, wherein the active ingredients of the composition include phenylephrine hydrochloride, chlorpheniramine maleate, acetaminophen and dextromethorphan hydrobromide. Since phenylephrine hydrochloride can be degraded in the presence of oxygen, aldehydes, certain acids and metals, the phenylephrine hydrochloride is prepared by the present invention, and in the presence of citric acid or other acids, the phenylephrine hydrochloride is stable under the condition of pH value 4.5-5.0, preferably pH value 4.7-5.0. In addition, the suspension prepared by the method of the present invention has the advantages of simple preparation method, good stability, high dissolution of the drug and good therapeutic effect.
[0046] The invention has a special effect on fever, sore throat, nasal congestion, cough, runny nose, etc. However, it is not suitable for people under 4 years old, and those aged 4-6 years old should follow the doctor's advice.
[0047] Instruction manual drawings:
[0048] Figure 1 : 1 represents the dissolution curve of acetaminophen in suspension prepared in Example 1 of the present invention; 2 represents the dissolution curve of acetaminophen in suspension prepared in Example 2 in the specification of patent number "2007800304895";
[0049] Figure 2 : 1 represents the dissolution curve of the suspension phenylephrine hydrochloride prepared in Example 1 of the present invention; 2 represents the dissolution curve of the suspension phenylephrine hydrochloride prepared in Example 2 in the specification of patent number "2007800304895".
[0050] Figure 3: 1 represents the dissolution curve diagram of the suspension chlorpheniramine maleate prepared by embodiment 1 of the present invention; 2 represents the dissolution curve diagram of the suspension chlorpheniramine maleate prepared by embodiment 2 in the patent No. "2007800304895" specification.
[0051] Figure 4 : 1 represents the dissolution curve of dextromethorphan hydrobromide suspension prepared in Example 1 of the present invention; 2 represents the dissolution curve of dextromethorphan hydrobromide suspension prepared in Example 2 in the specification of patent No. "2007800304895". DETAILED DESCRIPTION
[0052] The following examples further describe and demonstrate embodiments within the scope of the present invention. These examples are given for illustrative purposes and are not to be construed as limiting the present invention.
[0053] The present invention can be prepared by the following non-limiting example methods:
[0054] Example 1 (preparation 1000ml)
[0055] prescription:
[0056]
[0057] Preparation method:
[0058] A. Take the prescribed amount of chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and sodium benzoate and place them in a clean container, add an appropriate amount of purified water at 55-65°C, stir until melted / or dissolved, add sorbitol, continue stirring for 20-60 minutes, let stand, filter, and obtain material 1;
[0059] B. Take the prescribed amount of microcrystalline cellulose and place it in a homogenizer, add an appropriate amount of purified water, and homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 2;
[0060] C. Transfer the above material 1 to material 2, and continue to homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 3;
[0061] D. Place glycerol in a clean container, add xanthan gum, stir until melted / or dissolved, add the prescribed amount of dextromethorphan hydrobromide, stir evenly, and stir at 55-65° C. for 30-60 minutes to obtain material 4;
[0062] E. Transfer material 3 to material 4, add the prescribed amount of sucralose, brilliant blue, allura red and grape essence, add purified water to the preparation amount, stir for 100-150 minutes, adjust the pH value to 4.7-5.0 with anhydrous citric acid, continue stirring until homogeneous, filter, and obtain the present invention.
[0063] Example 2
[0064] prescription:
[0065]
[0066] A. Take the prescribed amount of chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and sorbic acid and place them in a clean container, add an appropriate amount of purified water at 55-65°C, stir until melted / or dissolved, add sorbitol, continue stirring for 20-60 minutes, let stand, filter, and obtain material 1;
[0067] B. Take the prescribed amount of microcrystalline cellulose and place it in a homogenizer, add an appropriate amount of purified water, and homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 2;
[0068] C. Transfer the above material 1 to material 2, and continue to homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 3;
[0069] D. Place glycerol in a clean container, add polyethylene glycol, stir until melted / dissolved, add the prescribed amount of dextromethorphan hydrobromide, stir evenly, and stir at 55-65° C. for 30-60 minutes to obtain material 4;
[0070] E. Transfer material 3 to material 4, add the prescribed amount of stevioside, tartrazine, and orange flavor, add purified water to the preparation amount, stir for 100-150 minutes, adjust the pH value to 4.5-5.0 with anhydrous citric acid, continue stirring until homogeneous, filter, and obtain the present invention.
[0071] Example 3
[0072]
[0073] A. Take the prescribed amount of chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and benzoic acid and place them in a clean container, add an appropriate amount of purified water at 55-65°C, stir until melted / or dissolved, add propylene glycol, continue stirring for 20-60 minutes, let it stand, filter, and obtain material 1;
[0074] B. Take the prescribed amount of hydroxypropyl methylcellulose and put it in a homogenizer, add an appropriate amount of solvent, and homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 2;
[0075] C. Transfer the above material 1 to material 2, and continue to homogenize and stir with a homogenizer (10000-20000r / s) for 20-50s to obtain material 3;
[0076] D. Place glycerol in a clean container, add xanthan gum, stir until melted / or dissolved, add the prescribed amount of dextromethorphan hydrobromide, stir evenly, and stir at 55-65° C. for 30-60 minutes to obtain material 4;
[0077] E. Transfer material 3 to material 4, add the prescribed amount of sucralose, brilliant blue, grape essence, add purified water to the preparation amount, stir for 100-150 minutes, adjust the pH value to 4.5-5.0 with sodium dihydrogen phosphate, continue stirring until homogeneous, filter, and obtain the present invention.
[0078] Example 4
[0079] The suspension prepared in Example 1 and the suspension prepared in Example 2 in the specification of patent number "2007800304895" and patent name "Pharmaceutical suspension containing phenylephrine and preparation method thereof" (hereinafter referred to as the patent method) were respectively tested for dissolution of phenylephrine hydrochloride, chlorpheniramine maleate, acetaminophen and dextromethorphan hydrobromide, and the solubility of the drugs at different times was compared.
[0080] Dissolution test method: HPLC method;
[0081] Dissolution curve test conditions:
[0082] Dissolution medium: 0.1mol / L hydrochloric acid, medium usage: 900ml; basket speed: 50 rpm; sampling volume: 10ml; sampling interval: 5min; 10min; 20min; 30min; 45min; 60min.
[0083] Detection conditions: chromatographic column C18; detection wavelength: 270nm; mobile phase A: buffer salt (sodium dihydrogen phosphate 30mol / l: sodium octane sulfonate 2.5g / L): organic phase (methanol: acetonitrile 35: 65) 90: 10; mobile phase B: buffer salt (sodium dihydrogen phosphate 30mmol / l: sodium octane sulfonate 2.5g / L): organic phase (methanol: acetonitrile 35: 65) 20: 80; pH value: 3.0; column temperature: 30℃
[0084] 1. Preparation of reference solution:
[0085] a. Preparation of acetaminophen reference solution:
[0086] Take 17.78 mg of acetaminophen reference substance and put it into a 50 ml volumetric flask, add an appropriate amount of diluent (mobile phase A), ultrasonicate for 5 minutes to completely dissolve it, make up to the mark, then take 1 ml into a 100 ml volumetric flask and make up to the mark with mobile phase A.
[0087] b. Preparation of phenylephrine hydrochloride reference substance:
[0088] Take 27.78 mg of phenylephrine hydrochloride reference substance and place it in a 50 ml volumetric flask, add an appropriate amount of diluent (mobile phase A), ultrasonicate for 5 minutes to completely dissolve it, dilute to the mark, then take 0.5 ml of the mixed reference solution to a 50 ml volumetric flask, dilute to the mark with mobile phase A, and that's it;
[0089] C. Take 11.11 mg of chlorpheniramine maleate reference substance and place it in a 50 ml volumetric flask. Prepare it in the same way as B.
[0090] D. Take 55.56 mg of dextromethorphan hydrobromide reference substance and place it in a 50 ml volumetric flask. Prepare it the same as B.
[0091] 2. Preparation of test solution:
[0092] Six portions of 0.1 mol / L hydrochloric acid dissolution medium were measured, each with 900 ml, and placed in 6 dissolution cups. They were heated. When the temperature of the dissolution medium was constant at 37°C, 10 ml of Example 1 was added to 3 cups, and 10 ml of the sample prepared by the "patented method" was added to the other 3 cups. The sampling time was set, and 5 ml was automatically sampled in each time period. The samples were taken in 6 times, filtered, and set aside.
[0093] 5. Test results: see the table below
[0094] Table of dissolution testing at different times
[0095]
[0096] Conclusion: HPLC test results are shown in the attached figure of the specification ( Figure 1 , Figure 2 , Figure 3 , Figure 4 ).
[0097] It can be seen from the test results that the suspension prepared in Example 1 of the present invention has a higher solubility than the suspension prepared by the patented method, especially the solubility of phenylephrine hydrochloride, chlorpheniramine maleate and acetaminophen is as high as more than 77%.
[0098] Example 5
[0099] Taking the content of phenylephrine hydrochloride as the detection object, the suspension prepared in Examples 1 to 4 was used to conduct stability investigation: Method:
[0100] Take 30 ml of each suspension prepared in Example 1 to Example 4, put them in a clean container, seal them, place them in a constant temperature box, and store them at 25°C, relative humidity 60%, 30°C, relative humidity 60%, 35°C, relative humidity ≤25%, 40°C, relative humidity 25%, and check the content of phenylephrine hydrochloride at different times.
[0101]
[0102] Conclusion: After 3-month and 6-month stability tests, the degradation rates of Examples 1 to 4 were 0.07%, 1.04%, 1.34% and 2.42%, respectively, among which the degradation rate of Example 1 was the lowest at 0.07%, and the total degradation rate did not exceed 3%.
[0103] It should be noted that although the above embodiments have illustrated and described specific embodiments of the present invention, it is obvious to those skilled in the art that changes in the amounts of other materials in the composition and changes in the dosage form may be made without departing from the spirit and scope of the present invention. Therefore, the claims are intended to include changes in all composition quantities and dosage forms within the scope of the present invention.
Claims
1. A preparation process for a composition comprising phenylephrine hydrochloride, characterized in that the preparation method is as follows: 1.1 Prescription: Each 1000ml of the composition contains: active pharmaceutical ingredients: 0.5g of phenylephrine hydrochloride, 0.2g of chlorpheniramine maleate, 32g of acetaminophen, 1.00g of dextromethorphan hydrobromide; excipients: 100g of glycerol, 670g of sorbitol, 1.125g of xanthan gum, 7.50g of microcrystalline cellulose, 1.2g of sodium benzoate, 2.4g of sucralose, 11.0mg of brilliant blue pigment, 28mg of allura red pigment, 2ml of grape essence, appropriate amount of anhydrous citric acid, and appropriate amount of purified water. 1.2 Preparation method: (1) Processing of raw materials and auxiliary materials: Paracetamol: crushed and passed through a 80-120 mesh sieve; Brilliant blue and allura red pigments, grape flavor: first prepared into a certain concentrated solution using solvent purified water; (2) Take the prescribed amount of chlorpheniramine maleate, phenylephrine hydrochloride, acetaminophen and sodium benzoate and place them in a clean container. Add an appropriate amount of purified water at 55-65°C and stir until it is melted or dissolved. Add sorbitol and continue stirring for 20-60 minutes. Let it stand and filter to obtain material 1. (3) Place the prescribed amount of microcrystalline cellulose in a homogenizer, add an appropriate amount of purified water, and homogenize and stir with the homogenizer for 20-50 seconds at a homogenization speed of 10000-20000 rpm to obtain material 2. (4) Transfer the above material 1 to material 2, and continue to homogenize and stir with a homogenizer for 20-50 seconds at a homogenization speed of 10000-20000 rpm to obtain material 3. (5) Place glycerol in a clean container, add xanthan gum, stir until melted or dissolved, add the prescribed amount of dextromethorphan hydrobromide, stir evenly, and stir at 55-65° C. for 30-60 minutes to obtain material 4. (6) Transfer material 3 to material 4, add the prescribed amount of sucralose, brilliant blue, allura red and grape essence, add purified water to the prepared amount, stir for 100-150 minutes, adjust the pH value to 4.7-5.0 with anhydrous citric acid, continue stirring until homogeneous, filter, and obtain.
Citation Information
Patent Citations
Pharmaceutical suspensions comprising phenylephrine and method of preparation
CN101505726A
Paracetamol, dextromethorphan hydrobromide and phenylephrine hydrochloride oral solution and preparation method thereof
CN109044968A
Medicine composition for treating cold symptoms such as running noses and nasal obstruction and preparation method and application of medicine composition
CN110279695A
Anti-cold drug suitable for children aged 4-11 years old and preparation method of drug
CN110302149A
Enhanced stability phenylephrine liquid compositions
US20080014274A1
